


# Impact of an expanded reimbursement policy on utilization of implantable loop recorders in patients with cryptogenic stroke in Korea

Hye Bin Gwag<sup>1</sup>, Nak Gyeong Ko<sup>2</sup>, and Mihyeon Jin<sup>2</sup>

<sup>1</sup>Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon; <sup>2</sup>Department of Research and Support, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

## Impact of an expanded reimbursement policy on utilization of implantable loop recorders in patients with cryptogenic stroke in Korea



### Conclusion

- The expanded coverage policy for CS had a significant impact on the number of ILR implantation for CS indication.
- The diagnostic yield of ILR for atrial fibrillation or flutter detection seems better when ILR is implanted within 2 months than later.
- Further investigation is needed to demonstrate other clinical benefits and the optimal ILR implantation timing.

**Background/Aims:** The reimbursement policy for cryptogenic stroke (CS) was expanded in November 2018 from recurrent strokes to the first stroke episode. No reports have demonstrated whether this policy change has affected trends in implantable loop recorder (ILR) utilization.

**Methods:** We identified patients who received an ILR implant using the Korea Health Insurance Review and Assessment Service database between July 2016 and October 2021. Patients meeting all the following criteria were considered to have CS indication: 1) prior stroke history, 2) no previous history of atrial fibrillation or flutter (AF/AFL), and 3) no maintenance of oral anticoagulant for  $\geq 4$  weeks within a year before ILR implant. AF/AFL diagnosed within 3 years after ILR implant or before ILR removal was considered ILR-driven.

**Results:** Among 3,056 patients, 1,001 (32.8%) had CS indications. The total ILR implant number gradually increased for both CS and non-CS indications and the number of CS indication significantly increased after implementing the expanded reimbursement policy. The detection rate for AF/AFL was 26.3% in CS patients over 3 years, which was significantly higher in patients implanted with an ILR within 2 months after stroke than those implanted later.

**Conclusions:** The expanded coverage policy for CS had a significant impact on the number of ILR implantation for CS indication. The diagnostic yield of ILR for AF/AFL detection seems better when ILR is implanted within 2 months than later. Further investigation is needed to demonstrate other clinical benefits and the optimal ILR implantation timing.

**Keywords:** Implantable loop recorder; Cryptogenic stroke; Health insurance reimbursement; Policy

## INTRODUCTION

Implantable loop recorders (ILRs) are small cardiac devices inserted into subcutaneous tissue to detect and record arrhythmic events for up to 3 years. The most common indications for ILR implantation are unexplained syncope, palpitation, and cryptogenic stroke (CS). In two real-world registries, ILRs were most frequently implanted because of syncope [1,2], but ILR also has proven its efficacy to detect atrial fibrillation in CS patients [3,4].

ILR implantation is currently reimbursed for 3 different indications in Korea: recurrent syncope, palpitation of unexplained cause, and CS. On November 2018, the reimbursement coverage for CS was expanded from “recurrent” to the first stroke episode. However, no nationwide reports have demonstrated whether this policy change has affected ILR utilization trends. We analyzed time-series trends in ILR implant before and after reimbursement policy change using the Korean Health Insurance Review & Assessment Service (HIRA) database. We also evaluated the diagnostic yield of ILR to detect atrial fibrillation or flutter (AF/AFL) in CS patients.

## METHODS

### Study population and data source

We obtained data from patients who were implanted with ILR between July 2016 and October 2021 from the HIRA database. HIRA collects medical information including patient age and sex, medical or surgical treatment, and diagnoses, which are coded according to the International Classification of Disease, Tenth Revision (ICD-10). The database, which includes almost the entire Korean population,

is available for researchers through the healthcare big data open system [5].

ILR implant was identified with the corresponding National Health Insurance (NHI) procedure codes (E6551 and E6553). ILR implant indications were classified to either CS or non-CS. CS was defined if all the following criteria were met: 1) stroke prior to ILR implant, 2) no history of AF/AFL before ILR implant, and 3) no maintenance of oral anticoagulant for  $\geq 4$  weeks within a year before ILR implant. The first diagnosis date of stroke (ICD-10: I63 or I64) was considered as the date of index stroke. Patients with CS indication were classified into 2 groups according to the interval from the index stroke to ILR implant; early implant ( $\leq 2$  mo) and late implant ( $> 2$  mo).


### Clinical variables and outcomes

Baseline characteristics were identified using the ICD-10 and prescription codes. A history of hypertension, diabetes mellitus, stroke, heart failure, cardiomyopathy, AF/AFL, myocardial infraction, peripheral arterial disease, and chronic kidney disease were assessed. We also assessed diagnostic tests before ILR implant using the NHI procedure code, which include 12-lead electrocardiogram, Holter-monitoring, transcranial Doppler, and trans-thoracic or -esophageal echocardiography. The primary outcome was temporal trends in ILR utilization following the expanded coverage policy for ILR implantation according to implant indication (CS or non-CS). We also investigated AF/AFL incidence to assess the diagnostic yield of ILR in CS patients as a secondary outcome. Atrial fibrillation or flutter diagnosed within 3 years after ILR implant or before ILR removal was considered ILR-driven.

### Statistical analysis

Categorical variables were presented as numbers and per-

centages and continuous variables were shown as means with standard deviation. We used the  $\chi^2$  test for comparison of categorical variables and the t-test for continuous variables. A segmented linear regression analysis of inter-



**Figure 1.** Flow chart of the study population. ILR, implantable loop recorder.

rupted time-series was performed to estimate the impact of the policy change on ILR utilization for each non-CS and CS indication. Cumulative incidence was estimated using the Kaplan-Meier estimator for AF/AFL (and hazard ratios were determined using the log-rank test). *p* values less than 0.05 at a 2-sided significance level were considered significant. SAS 9.4 version (SAS institute Inc., Cary, NC, USA) was used for all statistical analyses.

## Ethics statement

The Institutional Review Board at Samsung Changwon Hospital approved the study protocol (IRB No. 2022-03-008) and waived informed consent because the study was performed using a de-identified database.

## RESULTS

### Patient baseline characteristics

A total of 3,056 individuals were implanted with ILR between July 2016 and October 2021. Among 1,404 patients with prior stroke, 1,001 (32.8%) were classified to have CS

**Table 1. Baseline characteristics of total patient**

Variable	Total (n = 3,056)	CS (n = 1,001)	Non-CS (n = 2,055)	<i>p</i> value
Age (yr)	63.3 ± 15.3	65.9 ± 12.2	62.0 ± 16.5	< 0.001
Male	1,861 (60.9)	638 (63.7)	1,223 (59.5)	0.025
Hypertension	2,349 (76.9)	841 (84.0)	1,508 (73.4)	< 0.001
Diabetes	1,950 (63.8)	711 (71.0)	1,239 (60.3)	< 0.001
Heart failure	1,107 (36.2)	302 (30.2)	805 (39.2)	< 0.001
Atrial fibrillation or flutter	762 (24.9)	0 (0)	762 (37.1)	< 0.001
Myocardial infarction	307 (10.1)	95 (9.5)	212 (10.3)	0.476
Peripheral artery disease	589 (19.3)	365 (17.8)	224 (22.4)	0.002
CHA <sub>2</sub> DS <sub>2</sub> VASc score	3.6 ± 1.9	4.3 ± 1.7	3.3 ± 2.0	< 0.001
Chronic kidney disease	188 (6.2)	76 (7.6)	112 (5.5)	0.021
Pre-diagnostic tests				
Electrocardiogram	3,039 (99.4)	996 (99.5)	2,043 (99.5)	0.768
Holter-monitoring	2,909 (95.2)	965 (96.4)	1,944 (94.6)	0.029
Echocardiography	1,662 (54.4)	537 (53.7)	1,125 (54.7)	0.567
Trans-thoracic	1,600 (52.36)	501 (50.05)	1,099 (53.48)	0.075
Trans-esophageal	336 (11.0)	147 (14.7)	189 (9.2)	< 0.001
Transcranial Doppler	561 (18.4)	296 (29.6)	265 (12.9)	< 0.001

Values are presented as mean ± standard deviation or number (%).


CS, cryptogenic stroke.

*p* value refers to the difference between the CS and non-CS groups.

indication (Fig. 1). Baseline patient characteristics are shown in Table 1. The mean age of the total population was 63 years and the prevalence of hypertension and diabetes were 76.9% and 63.8%, respectively.

Compared to those with non-CS indication, patients with CS were older, more frequently men, and had higher prevalence of comorbidities including hypertension, diabetes,

peripheral artery disease, and chronic kidney disease. The CHA<sub>2</sub>DS<sub>2</sub>-VASc score was also significantly higher in patients with CS than in those without ( $4.3 \pm 1.7$  vs.  $3.3 \pm 2.0$ ,  $p < 0.001$ ). Before ILR implant, the majority of patients underwent rhythm monitoring using 12-lead electrocardiogram or Holter monitoring, while echocardiography was performed in only about half the patients. Holter monitoring




**Figure 2.** The number of ILR implantations for each indication. (A) Total number of ILR implants for each indication. (B) The ratio of CS and non-CS indications to total implantations. The dashed line indicates the implementation of the new expanded policy. ILR, implantable loop recorder; CS, cryptogenic stroke.

**Table 2. Interrupted time-series analysis of the impact of the expanded reimbursement policy on the number of implantable loop recorder implantations per 4 months**

Implant indication	$\beta_1$	SE	$p$ value	$\beta_2$	SE	$p$ value	$\beta_3$	SE	$p$ value
Cryptogenic stroke	0.20	0.13	0.117	6.23	2.71	0.025	0.28	0.15	0.073
Non-cryptogenic stroke	0.66	0.15	< 0.001	2.52	3.14	0.425	0.00	0.18	0.994

SE, standard error.



**Figure 3.** Trends in total ILR implant number every 4 months according to each indication. The vertical dashed line indicates the implementation of the new expanded policy. ILR, implantable loop recorder.

and trans-esophageal echocardiography were performed more frequently in patients with CS than in those with non-CS indication.

### Trends in ILR utilization according to implant indication

The total number of ILR implants for each indication has gradually increased over time except for a period of stagnation during the COVID-19 pandemic and a noticeable jump after the policy change. The ratio of CS indications to total indications has also gradually increased following the introduction of the new expanded policy, while that of non-CS has remained stationary (Fig. 2). In the CS indication group, the implant number significantly increased by 6.2 per 4 months ( $p = 0.025$ ), and the slope of the implant number increased but without statistical significance ( $p = 0.073$ ) after the policy change. The implant number in the non-CS indication group increased significantly before the policy change ( $p < 0.001$ ), but it became insignificant after the policy change (Table 2, Fig. 3).

### Characteristic of CS patients according to implant period

Among 1,001 patients with CS indication, 844 (84.3%) underwent ILR implantation after the policy change, and 232 (23.2%) underwent implantation within 2 months after their index stroke. Patients implanted with ILR after the policy change were younger and showed lower prevalences of diabetes and heart failure resulting in lower CHA<sub>2</sub>DS<sub>2</sub>VASc score compared with those implanted before the policy change. The mean time between stroke and ILR was 3.6 years, which was significantly longer before than after the policy change (4.5 vs. 3.5 yr,  $p = 0.007$ ). The rate of early implant ( $\leq 2$  months after index stroke) was also significantly higher in those who underwent ILR implant after the policy change (25.2% vs. 12.1%,  $p < 0.001$ ). Holter monitoring and trans-thoracic or -esophageal echocardiography were performed more frequently before than after the policy change (Table 3). Baseline patient characteristics according to the interval from the index stroke to ILR implant are shown in Supplementary Table 1.

**Table 3. Characteristics of cryptogenic stroke patients before and after the reimbursement expansion for implantable loop recorder**

Variable	Total (n = 1,001)	Before (n = 157)	After (n = 844)	<i>p</i> value
Age (yr)	65.9 ± 12.2	68.1 ± 11.3	65.5 ± 12.4	0.016
Male	638 (63.7)	101 (64.3)	537 (63.6)	0.866
Hypertension	841 (84.0)	140 (89.2)	701 (83.1)	0.055
Diabetes	711 (71.0)	124 (79.0)	587 (69.6)	0.017
Heart failure	302 (30.2)	63 (40.1)	239 (28.3)	0.003
Myocardial infarction	95 (9.5)	21 (13.4)	74 (8.8)	0.071
Peripheral artery disease	224 (22.4)	43 (27.4)	181 (21.5)	0.101
CHA <sub>2</sub> DS <sub>2</sub> VASc score	4.3 ± 1.7	4.8 ± 1.6	4.3 ± 1.7	< 0.001
Chronic kidney disease	76 (7.6)	13 (8.3)	63 (7.5)	0.723
Stroke to implantation (d)	1,331 ± 1,503	1,629 ± 1,354	1,275 ± 1,524	0.007
Early implant ( $\leq 2$ mo)	232 (23.2)	19 (12.1)	213 (25.2)	< 0.001
Late implant ( $> 2$ mo)	769 (76.8)	138 (87.9)	631 (74.8)	< 0.001
Pre-diagnostic tests				
Electrocardiogram	996 (99.5)	156 (99.4)	840 (99.5)	0.575
Holter-monitoring	965 (96.4)	146 (93.0)	819 (97.0)	0.013
Echocardiography	537 (53.7)	60 (38.2)	477 (56.5)	< 0.001
Trans-thoracic	501 (50.1)	58 (37.0)	443 (52.5)	< 0.001
Trans-esophageal	147 (14.7)	10 (6.37)	137 (16.2)	0.001
Transcranial Doppler	296 (29.6)	19 (12.1)	277 (32.8)	< 0.001

Values are presented as mean ± standard deviation or number (%).

*p* value refers to the difference between before and after the reimbursement expansion.

### Diagnostic yield of ILR in patients with CS

During the first 3 months after ILR implant, AF/AFL was detected in 130 (13.0%) patients. The diagnosis rate at 3 years was 26.3% in all CS patients. Kaplan-Meier curves comparing the cumulative incidence of AF/AFL between the 2 groups according to implant time and interval from index stroke over a 3-year period are shown in Figure 4. There was no difference in AF/AFL incidence between patients who underwent ILR implantation before and after the policy change. However, the early implant group showed a significantly higher AF/AFL incidence compared with the late implant group (hazard ratio 1.47, 95% confidence interval 0.50–0.85,  $p = 0.001$ ). The mean time intervals between stroke and anticoagulation initiation (13.6 vs. 72.1 mo,  $p < 0.001$ ) and between ILR implant and anticoagulation initiation (12.7 vs. 13.4 mo,  $p = 0.048$ ) were significantly shorter in the early implant compared to the late implant group.


### DISCUSSION

This nationwide cohort study investigated the ILR utilization in Korea between July 2016 and October 2021. The main findings were: 1) total ILR implant number gradually increased for both CS and non-CS indications; 2) about a third of patients underwent ILR implantation for CS indication and the number of ILR implantation for CS indication significantly increased after the expanded reimbursement

policy was implemented in November 2018; and 3) the diagnostic yield of ILR for AF/AFL detection was 26.3% in CS patients over 3 years, which was significantly higher among early implants compared to the late implant group.

In this study, we first evaluated whether implementation of a policy to allow ILR implant for the first stroke instead of only after recurrent stroke resulted in an increase in ILR usage in CS patients in Korea. The number of ILR implants for CS indication significantly increased after the policy change, and CS recently accounted for almost a third of all ILR implantation indications, which is a three-fold increase from when reimbursement began. The stroke-to-ILR implant interval also significantly decreased after the policy change, which possibly resulted in younger patients with ILR implants after the policy change than before.

There is a clinical significance of AF/AFL detection in CS patients because it has an impact on secondary stroke prevention, which is possibly associated with higher anticoagulation incidence, although controversial [6,7]. The AF/AFL detection rate in our cohort was similar or relatively higher than in previous studies, which showed that most AF detections by ILR occurred during the first few months [8-12]; however, the cumulative incidence of AF detection continued to increase over a year, albeit slowly. Our study results were also consistent with these findings, but the most distinct observation from our study population was that the interval from the index stroke to ILR implant was remarkably long [3,4,9-13]. This is not only because of the different study design and population in our study, but also because



**Figure 4.** Cumulative incidences of AF/AFL detection according to (A) implant period and (B) timing in CS patients. AF/AFL, atrial fibrillation or flutter; CS, cryptogenic stroke.  $p$  value refers to the result of the log-rank test between 2 groups.

ILR implants were reimbursed for only recurrent stroke until November 2018 in Korea. The reason why the interval was substantially long even after the policy change is likely because “recurrent” stroke still accounted for a large portion of CS indications, especially in the early period after the policy change. This might explain why the AF/AFL detection rate was not different despite the fact that the expanded policy led to a significant increase in ILR implant for CS. Considering that the detection rate was significantly higher in the early than in the late implant group, it is possible that the policy change impacted the AF/AFL detection rate in CS patients. However, ILR still seems useful to detect AF/AFL in patients after a long interval between stroke and ILR implant, presumably those who experienced recurrent stroke, even though the diagnostic yield in AF detection was higher in patients who were implanted with ILR within 2 months after their stroke. The interval from the stroke to ILR implant was still long in patients with non-recurrent events (mean 1,289 d). We attribute this to the relatively late timing of ILR insertion for CS in Korea, partly because of possible time lag between policy change and implementation in clinical practice.

A significant portion of CSs is attributed to cardioembolism. Cardioembolic stroke has a worse prognosis than strokes of other etiologies, and has higher risk of recurrence, severe disability, and mortality; thus, CS warrants comprehensive evaluation, particularly cardiac diagnostics [14-18]. However, echocardiography was performed in just over half of CS patients against our expectations, which was one of the major differences in our study from previous studies. Nevertheless, those studies included a relatively small number of patients from a single or limited number of centers or they had a prospective study design following a recommended protocol, while our study is a nationwide population-based retrospective cohort study [4,9,12,13,19]. Therefore, our study likely reflects the real-world practice for CS work-up in Korea. There is another possibility that other imaging modalities such as cardiac magnetic resonance imaging or computed tomography were performed as an alternative to echocardiography. For example, transcranial Doppler exam was performed in 29.6% of CS patients.

This study has several limitations. First, stroke etiology could not be confirmed because of the inherent limitations of claims data. The etiology of the study population is most likely to be cryptogenic considering the indications for ILR implantation coverage in Korea. We also incorpo-

rated 2 other criteria, including no prior history of AF/AFL and anticoagulation, to increase validity. However, patients with prior stroke, whether cryptogenic or not, could have a non-CS indication for ILR implantation. Second, we presumed that atrial fibrillation or flutter diagnosed after ILR implant was ILR-driven. However, we cannot confirm that all those events were detected by ILR nor which criteria were used for clinical diagnosis of AF/AFL in terms of duration [4]. Third, there was a chance of missing diagnoses of AF/AFL in patients without regular ILR interrogation. Lastly, we could not evaluate whether AF/AFL detection by ILR is beneficial for patient improving clinical outcomes including secondary stroke prevention.

This study investigated temporal trends and changes in ILR utilization following the expanded coverage policy for ILR implantation. We identified that the number of ILR implantations for CS indication significantly increased after the expanded reimbursement policy and CS accounted for a third of all indications. We also showed that the incidence of AF/AFL detection was higher when ILR was implanted within 2 months from the index stroke than after more than 2 months. We hope that our findings can be the basis for further studies to demonstrate the clinical benefit of AF/AFL detection using ILR and to determine the best timing of ILR implantation.

## KEY MESSAGE

1. The total ILR implant number has gradually increased for both CS and non-CS indications.
2. The number of ILR implantation for CS indication significantly increased after the expanded reimbursement.
3. The diagnostic yield of ILR for atrial fibrillation detection was 26.3%, which was significantly higher when ILR was implanted within 2 months than later.

## REFERENCES

1. Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. *Europace* 2011;13:262-269.

2. Lacunza-Ruiz FJ, Moya-Mitjans A, Martínez-Alday J, et al. Implantable loop recorder allows an etiologic diagnosis in one-third of patients. Results of the Spanish reveal registry. *Circ J* 2013;77:2535-2541.
3. Buck BH, Hill MD, Quinn FR, et al. Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PERDIEM randomized clinical trial. *JAMA* 2021;325:2160-2168.
4. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med* 2014;370:2478-2486.
5. Kim HK, Song SO, Noh J, Jeong IK, Lee BW. Data configuration and publication trends for the Korean National Health Insurance and Health Insurance Review & Assessment database. *Diabetes Metab J* 2020;44:671-678.
6. Tsvigoulis G, Katsanos AH, Gropy BM, et al. Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. *Stroke* 2019;50:2175-2180.
7. Huang WY, Ovbiagele B, Hsieh CY, Lee M. Association between implantable loop recorder use and secondary stroke prevention: a meta-analysis. *Open Heart* 2022;9:e002034.
8. Jiang H, Tan SY, Wang JK, et al. A meta-analysis of extended ECG monitoring in detection of atrial fibrillation in patients with cryptogenic stroke. *Open Heart* 2022;9:e002081.
9. Skrebelyte-Strøm L, Rønning OM, Dahl FA, Steine K, Kjekshus H. Prediction of occult atrial fibrillation in patients after cryptogenic stroke and transient ischaemic attack: PROACTIA. *Europace* 2022;24:1881-1888.
10. Kim JG, Boo K, Kang CH, Kim HJ, Choi JC. Impact of neuroimaging patterns for the detection of atrial fibrillation by implantable loop recorders in patients with embolic stroke of undetermined source. *Front Neurol* 2022;13:905998.
11. Ahluwalia N, Graham A, Honarbakhsh S, et al. Contemporary practice and optimising referral pathways for implantable cardiac monitoring for atrial fibrillation after cryptogenic stroke. *J Stroke Cerebrovasc Dis* 2022;31:106474.
12. Samaan S, Kohli U, Nazeer B, et al. Detection of atrial fibrillation by implantable loop recorders following cryptogenic stroke: a retrospective study of predictive factors and outcomes. *J Electrocardiol* 2022;71:54-58.
13. Dulai R, Hunt J, Veasey RA, Biyanwila C, O'Neill B, Patel N. Immediate implantable loop recorder implantation for detecting atrial fibrillation in cryptogenic stroke. *J Stroke Cerebrovasc Dis* 2023;32:106988.
14. Navi BB, Singer S, Merkler AE, et al. Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke. *Stroke* 2014;45:2292-2297.
15. Arboix A, Alió J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. *Curr Cardiol Rev* 2010;6:150-161.
16. Stöllberger C, Finsterer J. Detection of paroxysmal atrial fibrillation and patent foramen ovale in cryptogenic stroke. *Eur J Neurol* 2009;16:160-161.
17. Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. *Lancet Neurol* 2014;13:429-438.
18. Katsanos AH, Bhole R, Frogoudaki A, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. *Neurology* 2016;87:988-995.
19. Bettin M, Dechering D, Kochhäuser S, et al. Extended ECG monitoring with an implantable loop recorder in patients with cryptogenic stroke: time schedule, reasons for explantation and incidental findings (results from the TRACK-AF trial). *Clin Res Cardiol* 2019;108:309-314.

Received : November 6, 2023

Revised : January 14, 2024

Accepted : January 17, 2024

#### Correspondence to

Hye Bin Gwag, M.D., Ph.D.

Division of Cardiology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158 Paryong-ro, Masanhoewon-gu, Changwon 51353, Korea

Tel: +82-55-233-5821, Fax: +82-55-233-5040

E-mail: tgfbk@naver.com

<https://orcid.org/0000-0001-5610-2872>

#### Acknowledgments

The authors appreciate the Korean Health Insurance Review & Assessment Service for providing the data.

#### CRedit authorship contributions

Hye Bin Gwag: conceptualization, methodology, investigation, formal analysis, validation, writing - original draft, writing - review & editing, project administration, funding acquisition; Nak Gyeong Ko: methodology, investigation, data curation, formal analysis; Mihyeon Jin: investigation, data curation, formal analysis

#### Conflicts of interest

The authors disclose no conflicts.

#### Funding

This study was supported by Sungkyunkwan University School of Medicine Samsung Changwon Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.